水凝胶负载干细胞外泌体在组织再生领域的应用研究进展

近年来,间充质干细胞(mesenchymal stem cells,MSCs)衍生的外泌体在组织再生领域引发许多关注。MSCs衍生外泌体作为细胞间通讯的信号分子,具有天然靶向性强、免疫原性低等特点,其通过MSCs旁分泌途径被细胞吸收,参与调控发挥促进细胞或组织再生功能。水凝胶作为再生医学领域的支架材料,具有良好的生物相容性、降解性等特点。将二者制成复合物联合使用后不仅可以提高外泌体在病变位置的滞留时间,且可通过原位注射等方法提高外泌体到达病变位置的剂量,在病变区域治疗效果显著且持续性改善。文中总结了现阶段外泌体与水凝胶复合物材料共同作用促进组织修复、再生的研究结果,以期为未来组织再生领域中的相关研究工作提供借鉴。     

肌源干细胞及其应用研究进展

研究证实,肌肉中存在2种类型的干细胞,即肌卫星细胞和多能干细胞,后者又可分为不同的细胞亚群。这些细胞群表现出自我更新能力和多潜能性,可分化为血细胞、成骨细胞、神经细胞等不同胚层的组织细胞。由于肌源干细胞具有治疗包括骨骼肌和心肌在内的肌肉疾病的可能性,并且潜在地可促进其他组织,如骨和软骨的再生和愈合,因此近几年来的相关研究取得很大进展。     

外泌体在皮肤修复与再生中作用的研究进展

外泌体是直径在30-100 nm左右的囊泡结构。作为一种活细胞分泌的亚细胞成分,外泌体广泛参与细胞之间的交流,并可以作为干细胞的旁分泌因子来发挥生物学效应。研究发现外泌体可以参与皮肤组织修复与再生的各个过程,通过促进皮肤细胞的增殖迁移,促进血管新生,调节免疫反应来促进创伤愈合与皮肤组织再生,为进一步实现无细胞治疗提供了新的实现途径。对于某些慢性创面,例如糖尿病性皮肤溃疡等也有较好的治疗效果。本文就外泌体在皮肤修复与再生中作用的研究进展做一综述。     

诱导性多能干细胞的研究进展及其在再生医学上的应用

通过特定转录因子的过表达使体细胞重编程为诱导性多能干细胞(induced pluripotent stem cells,iPS细胞),这一成果引起了整个生命科学领域的广泛关注.由于iPS细胞不仅具有与人类胚胎干细胞(embryonicstem cell,ES细胞)相似的基本特征,而且与ES细胞相比,不存在免疫排斥和伦理道德问题,因此,具有重要的临床应用潜能.目前,iPS细胞主要用于细胞分化和移植,并可提供体外的疾病模型,以便于研究疾病形成的机制、筛选新药以及开发新的治疗方法.从iPS细胞的产生、诱导方法、生物学特征和在再生医学中的应用作以综述.     

间充质干细胞源性外泌体miRNAs参与损伤心血管细胞修复的研究进展

外泌体是由各种组织和细胞所释放的细胞外囊泡,在细胞之间充当各种分子(包括蛋白质,脂质和RNA)的载体,从而调节或干预特定的生理过程.MiRNAs是一类小的非编码RNA,能够靶向多个mRNA并诱导其降解或翻译抑制以调控相关基因表达.目前对外泌体内微小RNA(miR-NAs)的研究最为广泛.间充质干细胞(MSCs)是一种多...     

人尿源性干细胞的分离培养及应用研究新进展

人尿源性干细胞(human urine-derived stem cells,hUSCs)是从人尿液中通过常温离心分离培养出来的具有良好增殖活性和多向分化能力的成体干细胞,具有间充质干细胞的生物学特性,其在组织器官修复、疾病治疗、药物活性及毒性替代筛选等领域均有重要的应用前景,且已能实现多种途径向尿源性多潜能干细胞(urine-induced pluripotent stem cells,u-iPSCs)转化,但在研究过程中发现仍然存在一些值得深入研究的问题,如人尿液源性干细胞的来源尚不明确,定向诱导多潜能干细胞分化的条件选择及如何提高重编程效率等.本文对hUSCs的来源、分离培养方法、生物学特性及其应用研究最新进展进行综述,总结了由hUSCs向u-iPSCc诱导的方法及其应用前景,为hUSCs的研究和应用提供参考.     

间充质干细胞外泌体治疗肺部疾病的研究进展

肺部疾病作为一种呼吸系统常见病,与重工业快速发展、环境污染等密切相关,死亡率极高。近来研究发现间充质干细胞(mesenchymal stem cells,MSCs)能够自主归巢至疾病损伤部位、修复受损组织并参与调节全身炎症和免疫反应,在临床上有较好的应用前景。外泌体是一种细胞外膜囊泡,可能通过调节细胞间通讯参与生物系统中的各种活动,分泌至细胞外环境的外泌体也会影响宿主免疫系统。而MSCs外泌体作为MSCs旁分泌过程中的一种介质,携带有蛋白质、脂质、m RNA和microRNA等生物活性物质,比基于细胞的治疗有更高的安全性,其潜在的医学价值受到了研究者的广泛关注。本文综述了近年来研究中MSCs外泌体在常见肺部疾病治疗中的作用机制,将为其在未来的临床应用方面提供依据。     

Urine-derived stem/progenitor cells: A focus on their characterization and potential

Cell therapy, i.e., the use of cells to repair an affected tissue or organ, is at the forefront of regenerative and personalized medicine. Among the multiple cell types that have been used for this purpose [including adult stem cells such as mesenchymal stem cells or pluripotent stem cells], urine-derived stem cells (USCs) have aroused interest in the past years. USCs display classical features of mesenchymal stem cells such as differentiation capacity and immunomodulation. Importantly, they have the main advantage of being isolable from one sample of voided urine with a cheap and unpainful procedure, which is broadly applicable, whereas most adult stem cell types require invasive procedure. Moreover, USCs can be differentiated into renal cell types. This is of high interest for renal cell therapy-based regenerative approaches. This review will firstly describe the isolation and characterization of USCs. We will specifically present USC phenotype, which is not an object of consensus in the literature, as well as detail their differentiation capacity. In the second part of this review, we will present and discuss the main applications of USCs. These include use as a substrate to generate human induced pluripotent stem cells, but we will deeply focus on the use of USCs for cell therapy approaches with a detailed analysis depending on the targeted organ or system. Importantly, we will also focus on the applications that rely on the use of USC-derived products such as microvesicles including exosomes, which is a strategy being increasingly employed. In the last section, we will discuss the remaining barriers and challenges in the field of USC-based regenerative medicine.     

Recent advances in bone regeneration using adult stem cells

Bone is a highly vascularized tissue reliant on the close spatial and temporal association between bloodvessels and bone cells. Therefore, cells that participate in vasculogenesis and osteogenesis play a pivotal role in bone formation during prenatal and postnatal periods. Nevertheless, spontaneous healing of bone fracture is occasionally impaired due to insufficient blood and cellular supply to the site of injury. In these cases, bone regeneration process is interrupted, which might result in delayed union or even nonunion of the fracture. Nonunion fracture is difficult to treat and have a high financial impact. In the last decade, numerous technological advancements in bone tissue engineering and cell-therapy opened new horizon in the field of bone regeneration. This review starts with presentation of the biological processes involved in bone development, bone remodeling, fracture healing process and the microenvironment at bone healing sites. Then, we discuss the rationale for using adult stem cells and listed the characteristics of the available cells for bone regeneration. The mechanism of action and epigenetic regulations for osteogenic differentiation are also described. Finally, we review the literature for translational and clinical trials that investigated the use of adult stem cells(mesenchymal stem cells, endothelial progenitor cells and CD34+ blood progenitors) for bone regeneration.     

Mesenchymal stem cells in ischemic tissue regeneration

Diseases caused by ischemia are one of the leading causes of death in the world. Current therapies for treating acute myocardial infarction, ischemic stroke, and critical limb ischemia do not complete recovery. Regenerative therapies opens new therapeutic strategy in the treatment of ischemic disorders. Mesenchymal stem cells(MSCs) are the most promising option in the field of cell-based therapies, due to their secretory and immunomodulatory abilities, that contribute to ease inflammation and pr...     

Mesenchymal stem cells for cartilage regeneration in dogs

Articular cartilage damage and osteoarthritis (OA) are common orthopedic diseases in both humans and dogs. Once damaged, the articular cartilage seldom undergoes spontaneous repair because of its avascular, aneural, and alymphatic state, and the damage progresses to a chronic and painful situation. Dogs have distinctive characteristics compared to other laboratory animal species in that they share an OA pathology with humans. Dogs can also require treatment for naturally developed OA;therefore, effective treatment methods for OA are desired in veterinary medicine as well as in human medicine. Recently, interest has grown in regenerative medicine that includes the use of mesenchymal stem cells (MSCs). In cartilage repair, MSCs are a promising therapeutic tool due to their self-renewal capacity, ability to differentiate into cartilage, potential for trophic factor production, and capacity for immunomodulation. The MSCs from dogs (canine MSCs;cMSCs) share various characteristics with MSCs from other animal species, but they show some deviations, particularly in their differentiation ability and surface epitope expression. In vivo studies of cMSCs have demonstrated that intraarticular cMSC injection into cartilage lesions results in excellent hyaline cartilage regeneration. In clinical situations, cMSCs have shown great therapeutic effects, including amelioration of pain and lameness in dogs suffering from OA. However, some issues remain, such as a lack of regulations or guidelines and a need for unified methods for the use of cMSCs. This review summarizes what is known about cMSCs, including their in vitro characteristics, their therapeutic effects in cartilage lesion treatment in preclinical in vivo studies, their clinical efficacy for treatment of naturally developed OA in dogs, and the current limitations of cMSC studies.     

Floating culture promotes the maintenance of hematopoietic stem cells

In this study we examined the effect of the specific gravity of culture medium on the frequency of hematopoietic stem cell (HSC) maintenance. We used a newly developed high-specific-gravity media. Bone marrow cells were isolated and cultured, and HSC activity was evaluated. The number of hematopoietic progenitor/stem cells was markedly higher in the medium with high specific gravity. In high-specific-gravity media, cells did not precipitate, maintenance of HSCs was increased, and there was a concomitant accumulation of beta-catenin. This novel technique for maintaining HSC populations provides an important new tool for studies in regenerative medicine.     

Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: Role of secretome and exosomes

Over the last decades, mesenchymal stem cells (MSCs) have been extensively studied with regard to their potential applications in regenerative medicine. In rheumatic diseases, MSC-based therapy is the subject of great expectations for patients who are refractory to proposed treatments such as rheumatoid arthritis (RA), or display degenerative injuries without possible curative treatment, such as osteoarthritis (OA). The therapeutic potential of MSCs has been demonstrated in several pre-clinical models of OA or RA and both the safety and efficacy of MSC-based therapy is being evaluated in humans. The predominant mechanism by which MSCs participate to tissue repair is through a paracrine activity. Via the production of a multitude of trophic factors with various properties, MSCs can reduce tissue injury, protect tissue from further degradation and/or enhance tissue repair. However, a thorough in vivo examination of MSC-derived secretome and strategies to modulate it are still lacking. The present review discusses the current understanding of the MSC secretome as a therapeutic for treatment of inflammatory or degenerative pathologies focusing on rheumatic diseases. We provide insights on and perspectives for future development of the MSC secretome with respect to the release of extracellular vesicles that would have certain advantages over injection of living MSCs or administration of a single therapeutic factor or a combination of factors.     

Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine

Mesenchymal stem cells (MSCs) represent the most clinically used stem cells in regenerative medicine. However, due to the disadvantages with primary MSCs, such as limited cell proliferative capacity and rarity in the tissues leading to limited MSCs, gradual loss of differentiation during in vitro expansion reducing the efficacy of MSC application, and variation among donors increasing the uncertainty of MSC efficacy, the clinical application of MSCs has been greatly hampered. MSCs derived from human pluripotent stem cells (hPSC-MSCs) can circumvent these problems associated with primary MSCs. Due to the infinite self-renewal of hPSCs and their differentiation potential towards MSCs, hPSC-MSCs are emerging as an attractive alternative for regenerative medicine. This review summarizes the progress on derivation of MSCs from human pluripotent stem cells, disease modelling and drug screening using hPSC-MSCs, and various applications of hPSC-MSCs in regenerative medicine. In the end, the challenges and concerns with hPSC-MSC applications are also discussed.     

Immunological properties of embryonic and adult stem cells

The possibility of treating degenerative diseases by stem cell-based approaches is a promising therapeutical option. Among major concerns for the clinical application of stem cells, some derive from the possibility that stem cells may be rejected by the immune system as a consequence of histoincompatibility and that stem cells themselves may interfere with the normal functions of host immune response. Therefore, the immunogenicity and the immunomodulatory properties of stem cells must be carefully addressed. Although these properties are common features of different stem cell types, some peculiarities can be recognized and characterized for their proper clinical use.